Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Psychoneuroendocrinology ; 77: 203-210, 2017 03.
Article in English | MEDLINE | ID: mdl-28088659

ABSTRACT

Apolipoprotein E epsilon-4 (APOEε4 or APOE4), an allelic variation of the APOE gene, not only increases the risk of developing the late-onset form of Alzheimer's disease (AD), but also influences the outcome of treatment. Indeed, data from clinical studies show that the beneficial effect of insulin on cognition is blunted in APOE4 carriers. To investigate how APOE impacts insulin response, we assessed the effects of an acute insulin injection in APOE3- and APOE4-targeted replacement mice that respectively express the human APOE3 or APOE4 isoform instead of the endogenous murine ApoE protein. We evaluated cognition, insulin signaling and proteins implicated in Aß transport and tau phosphorylation in the cortex and brain capillaries. We found that a single acute insulin injection increased Akt pSer473 in APOE4 compared to APOE3 mice (+113% versus +78.5%), indicating that APOE4 carriage potentiates activation of insulin upstream signaling pathway in the brain. Insulin also led to decreased concentrations of the receptor for advanced glycation endproducts (RAGE) in brain capillaries in both groups of mice. Moreover, higher phosphorylation of tau at Ser202, one of the key markers of AD neuropathology, was observed in insulin-injected APOE4 mice (+44%), consistent with findings in human APOE4 carriers (+400% compared to non-carriers). Therefore, our data suggest that APOE4 carriage leads to an increased insulin-induced activation of cerebral Akt pathway, associated with higher AD-like tau neuropathology. Our results provide evidence of altered insulin signaling in APOE4 carriers as well as a possible mechanism to explain the absence of cognitive benefit from insulin therapy in these individuals.


Subject(s)
Apolipoprotein E3/genetics , Apolipoprotein E4/genetics , Cerebral Cortex/drug effects , Hypoglycemic Agents/pharmacology , Insulin/pharmacology , Animals , Cerebral Cortex/metabolism , Humans , Mice , Mice, Transgenic , Phosphorylation/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Receptor for Advanced Glycation End Products/metabolism , Receptor, Insulin/metabolism , tau Proteins/metabolism
2.
Vaccine ; 29 Suppl 4: D97-103, 2011 Dec 30.
Article in English | MEDLINE | ID: mdl-22284402

ABSTRACT

Interest and support for malaria control, eradication, and research has increased greatly over the past decade. This has resulted from appreciation of the huge medical, social, and economic burden that malaria exacts from endemic populations. Recent breakthroughs in drug development (artemisinin-based combination treatments), preventive interventions (long-lasting, insecticide-treated bed nets), improved diagnosis (rapid diagnostic tests), and community mobilization have resulted in deployment of new antimalarial tools. National programs supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria, the U.S. President's Malaria Initiative, and other donors have resulted in substantial reductions in malaria morbidity and mortality. Bill and Melinda Gates have given great impetus to eradication with support for the development of key research strategies and direct funding of innovative research projects, including malaria vaccine and drug discovery, that could decrease disease and transmission. Linking research to field operations is a strategy that succeeded for smallpox eradication and will be required for the demise of malaria.


Subject(s)
Disease Eradication/organization & administration , Disease Eradication/trends , Malaria/epidemiology , Malaria/prevention & control , Antimalarials/therapeutic use , Chemoprevention/methods , Drug Therapy/methods , Humans , Incidence , Malaria/drug therapy , Malaria/mortality , United States/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...